Navigation Links
Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women

SAN CARLOS, Calif., Aug. 13, 2014 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced a study to be published in the November issue of American Journal of Obstetrics and Gynecology, which shows that Panorama™ NIPT performs consistently well in all pregnant women, regardless of their prior risk level. This is the largest ever published study of clinical outcomes with NIPT, following more than 17,000 consecutive cases originally analyzed by Natera in mid-2013. It is also the second in a series of published studies showing strong test performance in low risk populations.

"This study supports the use of NIPT as a first line screening test for aneuploidy," said lead author Peer Dar, MD, Head of Fetal Medicine at Montefiore Medical Center in New York. "These results are consistent with recent NIPT guidelines published by the American College of Medical Genetics and Genomics (ACMG) that do not distinguish between high risk and low risk pregnancies, and which recommend NIPT in conjunction with first trimester ultrasound."

Key findings of this study:

  • Performance of the Panorama NIPT, determined previously in published case-controlled validation studies, has now been confirmed in a clinical setting with this study, the largest clinical outcomes study of NIPT to date. 
  • NIPT is already being adopted by some low-risk women and their healthcare providers, with 49% of the cases in this clinical study from women under 35 years of age.
  • The authors find that there are no concerns about performance of NIPT as a first line screen, and it will be accessibility and affordability that determine universal adoption.
  • The study highlighted an important performance metric: positive predictive value (PPV). Panorama's demonstrated PPV is significantly higher than traditional serum screening, by an order of magnitude. This should translate to a significant reduction in unnecessary invasive procedures and enhanced patient safety.

The results of this study, entitled "Clinical experience and follow-up with large scale single-nucleotide polymorphism-based non-invasive prenatal aneuploidy testing," by lead author Dr. Peer Dar and senior author, Dr. Peter Benn, are available online at

About Natera

Natera is a genetic testing company that designs targeted assays to analyze tiny quantities of DNA. The mission of the company is to help families diagnose and manage genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif., currently offering a host of preconception and prenatal genetic testing services primarily to OBGYN physicians and in-vitro fertilization centers. In 2013, the company launched Panorama™, a safe, simple test for pregnant women that screens for the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Tests developed by Natera have not been cleared or approved by the U.S. Food and Drug Administration (FDA). For more information, visit

GOLD PR for Natera
Shari Gold

Natera, Inc.
Mike Hromadik, 858-442-2215

SOURCE Natera, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
2. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
3. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
4. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
5. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
6. Cardiosolutions, Inc. Gathers Major Investment from Sorin Group
7. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
8. Misonix Exhibits at Major Worldwide Spine Conference
9. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
10. Aribex Reaches Major Milestone, Builds 10,000th NOMAD Handheld X-ray
11. Major Breakthrough in Hepatitis C Vaccine Development
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
Breaking Medicine News(10 mins):